November 10–11 | London
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to speak at the Financial Times Global Healthcare Summit in London. On November 10 at 13:30 PM, he will deliver an address and join the panel discussion titled "Longevity medicine — a new scientific frontier and biotech category?"
Longevity medicine has stepped from the periphery into the mainstream healthcare spotlight. Yet, the field remains caught in an uneasy space between rigorous science, preventive medicine, precision diagnostics, and high-end consumer demand: on one side are quantifiable, verifiable biomarkers and clinical endpoints; on the other lies an emerging consumer wellness boom. The boundaries, standards, and regulatory frameworks connecting the two have yet to be clearly established.
As one of the earliest researchers to treat biological aging itself as a starting point for therapeutic target discovery, Dr. Alex will share Insilico Medicine’s translational path at the summit. Compelling validation has already emerged from the Phase IIa study of Rentosertib, an anti-idiopathic pulmonary fibrosis (IPF) drug candidate: across six independently developed proteomic aging clocks, treated participants showed consistent directional changes in predicted biological age—findings published in Nature Biotechnology . Drawing on this case study, he will examine what evidence standards, clinical endpoint designs, and regulatory consensus are required for longevity medicine to be treated as a truly rigorous biotechnology sector.
About the Financial Times Global Healthcare Summit
This summit is the Financial Times' flagship annual gathering—formerly known as the FT Global Pharma and Biotech Summit—taking place on November 10–11, 2026, at Convene 22 Bishopsgate in London, with both in-person and virtual attendance options. Under the theme "Rewriting the rules of growth, access and innovation," this year’s edition is expected to bring together over 350 senior decision-makers from more than 260 companies, 60+ speakers, and FT journalists representing over 20 countries. The two-day agenda covers European competitiveness, pricing dynamics following US Most Favoured Nation policies, the role of AI in R&D and operations, direct patient access to medicines, China’s evolving role in drug development, and the future of the NHS.
November 11–12 | Abu Dhabi
Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has also been invited to attend Revive ME 2026 in Abu Dhabi. On the afternoon of November 11 at 1:50 PM, he will deliver a keynote address titled "Generative Biology: Using AI to accelerate longevity drug discovery."
Beyond merely interpreting biological data, AI must actively generate hypotheses, design molecules, and undergo empirical experimental validation to establish a closed-loop iterative cycle. Dr. Aliper will showcase how Insilico Medicine leverages its core Pharma.AI platform to apply generative models across aging-related target identification and longevity drug design: anchoring targets to hallmarks of aging, synthesizing novel chemical matter through generative chemistry, validating candidates rapidly via automated biology labs, and advancing these assets into clinical trials. He will also explore how the Middle East’s regional genomic data assets, precision medicine infrastructure, and dedicated longevity capital combine to create an ideal environment for accelerating this closed-loop paradigm.
About Revive ME 2026
Revive ME is the region’s premier conference and exhibition dedicated to healthy longevity and health technology, organized in strategic partnership with the Department of Health – Abu Dhabi. The summit addresses longevity science and aging biomarkers, regenerative medicine and cell therapies, precision medicine and genomics, AI-driven diagnostics and predictive health, preventive medicine and early disease detection, metabolic and cognitive health, digital health and remote patient monitoring, clinical implementation and reimbursement strategies, longevity investment and market intelligence, as well as regulatory frameworks and compliance. It serves as an essential nexus bridging scientific discoveries in the global longevity ecosystem with real-world clinical and commercial deployment.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK .
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com